FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2985385056> ?p ?o ?g. }

• W2985385056 abstract "Abstract Objective Monoclonal antibodies (MAbs) directed against the CD20 and CD52 antigens are used increasingly in patients with multiple sclerosis (MS). Several life-threatening opportunistic infections have been reported in postmarketing case series. The aim of this study was to investigate the incidence of infections and associated prognostic factors during the first year of treatment in patients receiving anti-CD20 (ocrelizumab or rituximab) or anti-CD52 MAbs (alemtuzumab). Methods A retrospective study was conducted in patients with MS referring to the Neurodegenerative Diseases Center at the University of Naples Federico II who received MAbs between November 2015 and June 2018. Results A total of 163 patients were enrolled. Approximately 40% of patients experienced lymphocytopenia during treatment. Eighty-six infective events were reported in 67 patients (41%). Bacterial infections were significantly more frequent with anti-CD20, whereas viral infections prevailed with alemtuzumab. Cytomegalovirus reactivation rates were significantly higher in the alemtuzumab group than in patients on anti-CD20 (51% vs 6%, P < .001). The overall annualized infection rate was 1.1 per patient-year, higher in patients on anti-CD52 versus those on anti-CD20 regimens (1.5 vs 0.8 per patient-year). Alemtuzumab treatment, prior exposure to ≥2 MS drugs, and iatrogenic immune impairment significantly and independently predicted an infection event (adjusted hazard ratio [aHR], 2.7; P = .013; aHR, 1.7; P = .052; and aHR, 2.9; P = .004; respectively). Conclusions Given their considerable infection risk, MS patients receiving MAbs should undergo timely follow up and tailored preventive interventions. Anti-CD52–based treatment, prior exposure to MS drugs, and on-treatment immune impairment are significant predictive factors of infection and their evaluation could help clinicians to stratify a patient’s risk of infection." @default.
• W2985385056 created "2019-11-22" @default.
• W2985385056 creator A5031247439 @default.
• W2985385056 creator A5031570157 @default.
• W2985385056 creator A5038531441 @default.
• W2985385056 creator A5049964338 @default.
• W2985385056 creator A5055284599 @default.
• W2985385056 creator A5057792540 @default.
• W2985385056 creator A5066109758 @default.
• W2985385056 creator A5067909605 @default.
• W2985385056 creator A5071429860 @default.
• W2985385056 creator A5090968901 @default.
• W2985385056 date "2019-10-21" @default.
• W2985385056 modified "2023-09-27" @default.
• W2985385056 title "Incidence and Predictive Risk Factors of Infective Events in Patients With Multiple Sclerosis Treated With Agents Targeting CD20 and CD52 Surface Antigens" @default.
• W2985385056 cites W1920355337 @default.
• W2985385056 cites W2073728662 @default.
• W2985385056 cites W2107008240 @default.
• W2985385056 cites W2141825709 @default.
• W2985385056 cites W2142577589 @default.
• W2985385056 cites W2158202057 @default.
• W2985385056 cites W2166356134 @default.
• W2985385056 cites W2166734004 @default.
• W2985385056 cites W2280404143 @default.
• W2985385056 cites W2318040644 @default.
• W2985385056 cites W2341417316 @default.
• W2985385056 cites W2556665052 @default.
• W2985385056 cites W2565433170 @default.
• W2985385056 cites W2604515581 @default.
• W2985385056 cites W2605414608 @default.
• W2985385056 cites W2605785536 @default.
• W2985385056 cites W2756612472 @default.
• W2985385056 cites W2759253724 @default.
• W2985385056 cites W2765494965 @default.
• W2985385056 cites W2771633521 @default.
• W2985385056 cites W2806952939 @default.
• W2985385056 cites W2807856802 @default.
• W2985385056 cites W2883892074 @default.
• W2985385056 cites W2895718288 @default.
• W2985385056 cites W2907790541 @default.
• W2985385056 doi "https://doi.org/10.1093/ofid/ofz445" @default.
• W2985385056 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6837838" @default.
• W2985385056 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31723572" @default.
• W2985385056 hasPublicationYear "2019" @default.
• W2985385056 type Work @default.
• W2985385056 sameAs 2985385056 @default.
• W2985385056 citedByCount "20" @default.
• W2985385056 countsByYear W29853850562019 @default.
• W2985385056 countsByYear W29853850562020 @default.
• W2985385056 countsByYear W29853850562021 @default.
• W2985385056 countsByYear W29853850562022 @default.
• W2985385056 countsByYear W29853850562023 @default.
• W2985385056 crossrefType "journal-article" @default.
• W2985385056 hasAuthorship W2985385056A5031247439 @default.
• W2985385056 hasAuthorship W2985385056A5031570157 @default.
• W2985385056 hasAuthorship W2985385056A5038531441 @default.
• W2985385056 hasAuthorship W2985385056A5049964338 @default.
• W2985385056 hasAuthorship W2985385056A5055284599 @default.
• W2985385056 hasAuthorship W2985385056A5057792540 @default.
• W2985385056 hasAuthorship W2985385056A5066109758 @default.
• W2985385056 hasAuthorship W2985385056A5067909605 @default.
• W2985385056 hasAuthorship W2985385056A5071429860 @default.
• W2985385056 hasAuthorship W2985385056A5090968901 @default.
• W2985385056 hasBestOaLocation W29853850561 @default.
• W2985385056 hasConcept C120665830 @default.
• W2985385056 hasConcept C121332964 @default.
• W2985385056 hasConcept C126322002 @default.
• W2985385056 hasConcept C18031839 @default.
• W2985385056 hasConcept C203014093 @default.
• W2985385056 hasConcept C207103383 @default.
• W2985385056 hasConcept C2778384904 @default.
• W2985385056 hasConcept C2779015954 @default.
• W2985385056 hasConcept C2779338263 @default.
• W2985385056 hasConcept C2780640218 @default.
• W2985385056 hasConcept C2780653079 @default.
• W2985385056 hasConcept C2911091166 @default.
• W2985385056 hasConcept C44249647 @default.
• W2985385056 hasConcept C61511704 @default.
• W2985385056 hasConcept C71924100 @default.
• W2985385056 hasConceptScore W2985385056C120665830 @default.
• W2985385056 hasConceptScore W2985385056C121332964 @default.
• W2985385056 hasConceptScore W2985385056C126322002 @default.
• W2985385056 hasConceptScore W2985385056C18031839 @default.
• W2985385056 hasConceptScore W2985385056C203014093 @default.
• W2985385056 hasConceptScore W2985385056C207103383 @default.
• W2985385056 hasConceptScore W2985385056C2778384904 @default.
• W2985385056 hasConceptScore W2985385056C2779015954 @default.
• W2985385056 hasConceptScore W2985385056C2779338263 @default.
• W2985385056 hasConceptScore W2985385056C2780640218 @default.
• W2985385056 hasConceptScore W2985385056C2780653079 @default.
• W2985385056 hasConceptScore W2985385056C2911091166 @default.
• W2985385056 hasConceptScore W2985385056C44249647 @default.
• W2985385056 hasConceptScore W2985385056C61511704 @default.
• W2985385056 hasConceptScore W2985385056C71924100 @default.
• W2985385056 hasIssue "11" @default.
• W2985385056 hasLocation W29853850561 @default.
• W2985385056 hasLocation W29853850562 @default.
• W2985385056 hasLocation W29853850563 @default.
• W2985385056 hasLocation W29853850564 @default.
• W2985385056 hasOpenAccess W2985385056 @default.

• next